Diagnosis, Treatment, and the Burden of Disease for Duchenne Muscular Dystrophy (DMD) in Females: A Targeted Literature Review (TLR)

Speaker(s)

Juntas Morales R1, Ferlini A2, Giliberto F3, Beitia Ortiz de Zarate I4, Graziadio S5, Edwards M5, Arber M5, Nieto Vázquez I6, Tomazos I7, Castellano P7, Zhang R8
1Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain, 2University of Ferrara, Ferrara, Emilia-Romagna, Italy, 3INIGEM UBA-CONICET, Buenos Aires, Buenos Aires, Argentina, 4PTC Therapeutics, Paris, France, 5York Health Economics Consortium, York, YOR, UK, 6PTC Therapeutics Spain S.L., Madrid, Madrid, Spain, 7PTC Therapeutics Inc, Warren, NJ, USA, 8PTC Therapeutics Sweden AB, Stockholm, AB, Sweden

OBJECTIVES: Research in DMD, a rare, X-linked disease, generally focuses on males. Though female carriers may experience symptoms, beyond recommendations for access to testing, guidelines for the management of DMD in females are sparse. This TLR sought to characterize the burden and management of female patients with DMD dystrophinopathy and carriers.

METHODS: Searches were conducted in June 2023 in eight databases using search terms for DMD and females. All retrieved records including case series and reports were screened. Studies reporting on disease burden, diagnostic pathways, treatment pathways, and outcomes were eligible. Newer papers (2015-2023) reporting on higher numbers of patients, with either detailed data or >1 outcome reported, were prioritised for extraction, and key guidelines were also synthesised.

RESULTS: From 2,058 records, 82 relevant papers were identified; 13 studies were extracted. Cardiac outcomes were common in carriers; the cardiac abnormality rate (variously defined) was 50% to 100% among 90 carriers across 4 studies. In a study comparing female carriers to males with a likely DMD mutation, mean age at dilated cardiomyopathy diagnosis was significantly later for females (p<0.001). Among carriers, ~8% had muscle symptoms (2 studies). Two studies, both using cognitive assessment tools in carriers and non-carriers, described reduced cognitive performance on some sub-domains among carriers relative to non-carriers. In 4 studies reporting diagnostic pathways, methods of diagnosis were not systematic.

CONCLUSIONS: This review indicates a large proportion of female patients with DMD dystrophinopathy and carriers are affected, especially by cardiac, but also by muscular and/or cognitive difficulties. Data on diagnostic pathways used was limited; pathways followed do not always reflect best practice. A limitation of this review is that case reports, which were not extracted, may contain information related to treatment pathways/outcomes. Our findings suggest that this population is under-investigated, and given their unmet medical need, additional research is necessary.

Code

PCR183

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Rare & Orphan Diseases